Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CRUZ Tunisia-Multivessel Registry

NCT: NCT06663696 · RECRUITING

NCT IDNCT06663696
StatusRECRUITING
Start Date2024-11-01
Completion2028-05

Brief Summary

The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).

Frequently Asked Questions

What is CRUZ Tunisia-Multivessel Registry?

CRUZ Tunisia-Multivessel Registry is a clinical trial registered under NCT06663696. Current status: RECRUITING.

What is the status of NCT06663696?

The current status of NCT06663696 (CRUZ Tunisia-Multivessel Registry) is: RECRUITING.

When did CRUZ Tunisia-Multivessel Registry start?

CRUZ Tunisia-Multivessel Registry started on 2024-11-01.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.